drugset
drugset / Trial / NCT06698939

ORKA-001 in Healthy Volunteers

NCT06698939 ↗

Phase 1 Completed 24 enrolled Oruka Therapeutics, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.

Timeline

Start
2024-12-19
Primary completion
2026-03-13
Completion
2026-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ORKA-001 Unknown 300 mg Subcutaneous
Subject ORKA-001 Unknown 600 mg Subcutaneous
Subject ORKA-001 Unknown 1200 mg Subcutaneous

Indications

No indication recorded.